• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biohit

2.65 EUR0.00 %14.8, 17.29
4,977 following

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
0.00 %
-6.03 %
+12.77 %
-9.25 %
-28.18 %
-12.83 %
+27.40 %
+12.29 %
-49.04 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
40.29M EUR
Turnover
6.4K EUR
P/E (adj.) (26e)
15.63
EV/EBIT (adj.) (26e)
12.73
P/B (26e)
2.28
EV/S (26e)
2.32
Dividend yield-% (26e)
1.92 %
Coverage
Recommendation
Accumulate
Target price
3.30 EUR
Updated
05.08.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 06.08.2026

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
A quick look at the past might be useful here. In the H1’24 report, I noticed that the balance sheet item “trade receivables and other receivables” grew by nearly 3 MEUR during the beginning of '24. I asked Jussi about this in an interview, and he mentioned strong sales in June (...
8/6/2026, 1:25 PM
by Antti Siltanen
19
Inderes BIOHIT-KONSERNIN PUOLIVUOSIKATSAUS 1.1.–30.6.2026 (tilintarkastamaton) -... BIOHIT-KONSERNIN PUOLIVUOSIKATSAUS 1.1.–30.6.2026 (tilintarkastamaton) Biohit Oyj Puolivuosikatsaus 2026 5.8.2026 klo 9:30 paikallista aikaa (EEST)YHTEENVETO Tammi–kesäkuu 2026Liikevaihto 7,... It...
8/5/2026, 6:43 AM
by Tunturisusi
13
I certainly agree that counterparty risk is always present, and it is true that it should be highlighted. In this case, it encompasses much more than just whether those cash flows will come in as estimated in the annual report. I have also been constantly monitoring these items and...
8/6/2026, 3:06 PM
by PeterPan
8
Quite right; it is good that you urge us investors to be cautious when you see cause for it
8/7/2026, 12:05 PM
by Hermot Lehman
6
Antti and Biohit’s CEO Jussi Hahtela discussed, among other things, Biohit’s results and outlook Topics: 00:00 Introduction 00:11 Key highlights of the beginning of the year 00:47 Market situation in the Middle East 01:41 Situation of subsidiaries in Europe 03:41 Chilean market 04...
8/5/2026, 12:10 PM
by Sijoittaja-alokas
6
Based on what you quoted from the annual report, it certainly seems that this is not about already invoiced receivables, but about expected cash flows based on contracts already made. This, of course, sounds much better than the accumulation of overdue receivables, which is how many...
8/6/2026, 12:00 PM
by Hermot Lehman
4
The increase in these items didn’t come as a surprise to me, at least. Furthermore, the way the money is starting to move as projected is quite clearly stated in Biohit’s annual report. Or perhaps I have misunderstood something. The following is stated in Biohit’s annual report: ...
8/6/2026, 11:42 AM
by PeterPan
4
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Biohit H1'26: Strong earnings clouded by weak cash flow
Research06.08.2026, 09.50 by
Antti Siltanen

Biohit H1'26: Strong earnings clouded by weak cash flow

Biohit's reported earnings were excellent, but cash flowed out of the company in the first half of the year.

Biohit
Regulatory press release05.08.2026, 08.30

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2026 (unaudited) 

Biohit
Biohit H1'26 preview: Moderate growth against weak comparison period
Analyst Comment31.07.2026, 07.23 by
Antti Siltanen

Biohit H1'26 preview: Moderate growth against weak comparison period

Chile's screening program accelerates revenue growth to 8% in our H1 estimate.

Biohit

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Biohit: Sold on summer sale
Research29.06.2026, 08.00 by
Antti Siltanen

Biohit: Sold on summer sale

The stock's valuation has fallen to a rather low level.

Biohit
Regulatory press release05.06.2026, 17.00

Constitutive meeting of Biohit Oyj’s Board of Directors

Biohit
Regulatory press release03.06.2026, 17.00

Decisions of the Annual General Meeting of Biohit Oyj

Biohit
Regulatory press release06.05.2026, 14.45

Correction: Notice of Biohit Oyj’s Annual General Meeting

Biohit
Regulatory press release06.05.2026, 14.06

Notice of Biohit Oyj’s Annual General Meeting

Biohit
Regulatory press release06.05.2026, 14.00

Notice of Biohit Oyj’s Annual General Meeting

Biohit
Study: Biohit's GastroPanel reduced waiting lists
Analyst Comment22.04.2026, 07.26 by
Antti Siltanen

Study: Biohit's GastroPanel reduced waiting lists

Endoscopy wait times were reduced by 87%.

Biohit
Press release21.04.2026, 13.00

A peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy waiting lists

Biohit
Regulatory press release01.04.2026, 13.00

Biohit Plc B-shares Subscribed with Stock Options I 2021D

Biohit
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026, 11.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release18.03.2026, 08.30

Publication of Biohit Oyj Annual Report 2025

Biohit
Regulatory press release18.03.2026, 08.30

Publication of Biohit Oyj Remuneration Report 2025

Biohit
Press release11.03.2026, 12.00

Change in the Biohit Oyj Management Team

Biohit
Biohit H2'25: Strong earnings – more moderate growth outlook
Research12.02.2026, 09.16 by
Antti Siltanen

Biohit H2'25: Strong earnings – more moderate growth outlook

Biohit’s revenue was in line with our estimate, and earnings exceeded it.

Biohit
Regulatory press release11.02.2026, 08.30

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2025

Biohit
Biohit Q4'25 preview: Back on the growth path from the middle of a sandstorm
Analyst Comment06.02.2026, 08.27 by
Antti Siltanen

Biohit Q4'25 preview: Back on the growth path from the middle of a sandstorm

We estimate revenue growth to have accelerated to 21% in late 2025 due to easing delivery difficulties in the Middle East.

Biohit
We take advantage of Biohit's January sale
Research16.01.2026, 08.32 by
Antti Siltanen

We take advantage of Biohit's January sale

Biohit's share price has fallen and the risk/reward ratio has become attractive again.

Biohit